Previous studies on regulatory T-cell (Treg) reconstitution after allogeneic hematopoietic SCT (HSCT) have suggested that, within the GVHD process, imbalance between effector T cells and Tregs may be more important than the absolute numbers of circulating Tregs. No study has analyzed naive vs memory Treg reconstitution in a longitudinal cohort with large numbers of patients. The reconstitution of total and subsets of Treg was prospectively analyzed by flow cytometry in 185 consecutive recipients at 3, 6, 12 and 24 months after allogeneic HSCT. The levels of total, naive and memory Tregs increased, mainly within the memory subset, but remained lower than healthy controls up to 2 years after transplantation. Reduced-intensity conditioning and peripheral blood (PBSC) as the source of stem cells were associated with better 3-month reconstitution. In multivariate analysis, PBSC, recipient age ⩽ 25 and no anti-thymoglobulin in the conditioning regimen were associated with a better Treg reconstitution. Naive Treg long-term reconstitution was mainly influenced by recipient age. Whereas prior acute GVHD impaired Treg reconstitution, Treg subsets (absolute numbers and frequencies relative to CD4 + T-cell subsets) at 3, 6 and 12 months after HSCT were not associated with the occurrence of a later episode of chronic GVHD.
INTRODUCTION
The potentially curative benefit of allogeneic hematopoietic SCT (HSCT) is counterbalanced by the risks of GVHD and infections. Regulatory T cells (Tregs) have been reported to have some role in the physiopathology of GVHD. In mouse models, it has been reported that Tregs can prevent GVHD 1 and clinical trials in humans have also been initiated. 2, 3 Several studies correlating Treg reconstitution and GVHD suggest that an imbalance between effector T cells and Tregs within the GVHD process may be more important than the absolute numbers of circulating Tregs. [4] [5] [6] [7] However, Tregs are a heterogeneous population. Indeed, just as for conventional T cells, naive (nTreg) and memory Treg (mTreg) subsets have already been described. 8 We have already studied long-term immune reconstitution after HSCT, but the Treg population was not described. 9 In this study, we analyzed the reconstitution of conventional and regulatory T cells and their naive and memory subsets in a longitudinal cohort including a large number of patients, and aimed to correlate Treg reconstitution with GVHD.
MATERIALS AND METHODS
We prospectively analyzed 185 consecutive patients, who underwent allogeneic HSCT at Hôpital Saint Louis, Paris, France between 2006 and 2009. Patients transplanted for sickle cell disease and patients who died in the first 3 months after HSCT were excluded. Patients who relapsed were excluded from the date of relapse. The study protocol was approved by the review board of Hôpital Saint Louis and the study was carried out in accordance with the Declaration of Helsinki.
Patient and transplant characteristics are presented in Table 1a . All patients received CsA as GVHD prophylaxis, with either MTX or mycophenolate mofetil. GVHD was defined as acute if it occurred before day 100 and chronic thereafter.
Lymphocytes were analyzed in three-or four-color immunofluorescence using a FACSCanto II flow with a FACSCalibur analyzer (BD Biosciences, San Jose, CA, USA) in fresh whole blood samples obtained 3 (n = 155), 6 (n = 162), 12 (n = 165) and 24 (n = 94) months after HSCT. 
RESULTS

Reconstitution of total, naive and memory Tregs
Total Tregs increased from 13/μL at 3 months to 44/μL at 24 months, but always remained lower than healthy controls (66.8/μL). Naive Tregs increased from 1.8/μL to 4.8/μL and mTregs from 10.7/μL to 33.3/μL at 3 and 24 months, respectively. The increase in total Tregs, nTregs and mTregs as well as naive CD4 (Figures 1a and b) . The CD4/Treg ratio was stable at 12.6 and 11.6 at 3 and 24 months. The nCD4/ nTreg ratio increased from 16.9 at 3 months to 25.5 at 12 months, showing both a larger increase of nCD4 + T cells than nTregs and a larger increase of mTregs than memory CD4 + T cells during the first year after transplantation. However, the nCD4/nTreg ratio then decreased to 12.3 at 24 months due to the stabilization of nCD4 + T cells, while the nTregs continued to increase ( Figure 1b ). In our population, there was no correlation between total Treg, nTreg and mTreg reconstitution and OS or non-relapse mortality.
Factors influencing Treg reconstitution At 3 months post HSCT, total Tregs, nTregs and mTregs were significantly higher in patients transplanted using PBSC (18.4, 2.7 and 14.5/μL, respectively) than in those who received BM (8.1, 0.9 and 6.5/μL) or cord blood (6.5, 0.6 and 5.3/μL) (P = 0.0001). Patients transplanted after a reduced-intensity conditioning regimen had significantly more total Tregs and mTregs than patients transplanted after a myeloablative conditioning regimen (17 and 14/μL vs 9.8 and 8/μL, P = 0.004 and 0.008, respectively). Patients transplanted for aplastic anemia had significantly fewer total Tregs, nTregs and mTregs than patients transplanted for a malignant disease (4.8 vs 14.4/μL for total Treg, 0.4 vs 1.9/μL for nTreg and 4.4 vs 11.2/μL for mTreg, P ⩽ 0.03). Total Treg and mTreg reconstitution was significantly better if the recipient was older than 25 years (15.4 vs 9.5/μL and 13.3 vs 7.4/μL for total Tregs and mTregs, respectively, P ⩽ 0.018). Total Treg and mTreg reconstitution was also significantly better if the donor was older than 25 years (15.8 vs 5.8/μL and 14.2 vs 7.8/μL, for total Tregs and mTregs, respectively, P ⩽ 0.02).
At 12 months, nTregs were significantly higher if the donor was aged 25 or younger (5.3 vs 2/μL, P = 0.007). At 12 and 24 months, recipient age ⩽ 15 years was associated with a better nTreg reconstitution (9.8 vs 2.1/μL at 12 months and 28.7 vs 4.2/μL at 24 months, P = 0.001).
At 24 months, patients transplanted for acute leukemia had significantly higher total Tregs, nTregs and mTregs than patients transplanted for other malignant hematological diseases (54.6, 6.8 and 40/μL vs 19, 1.4 and 14/μL, P ⩽ 0.01).
Reconstitution of total Tregs, nTregs and mTregs was significantly better at 3, 6 and 12 months in patients who had not received anti-thymoglobulin (ATG) during conditioning (at 3, 6 and 12 months: 15.7, 19.5 and 28.4/μL for total Tregs, 2.2, 1.9 and 3.2/μL for nTregs and 13.3, 17.5 and 23.4/μL for mTregs) compared with patients who had received ATG during conditioning (at 3, 6 and 12 months: 5, 9.6 and 20/μL for total Tregs, 0.4, 0.7 and 1/μL for nTregs and 1.3, 9.3 and 14.8/μL for mTregs) (P ⩽ 0.02). In our population, CMV serological status of donor and recipient and donor/recipient sex matching did not significantly influence Treg reconstitution.
In multivariate analysis, factors associated with a better Treg reconstitution (Table 1b ) from 3 to 12 months were PBSC, recipient age ⩽ 25 years and absence of ATG in the conditioning regimen. In patients with prior acute GVHD, total Tregs and mTregs were significantly lower at 3 and 6 months compared with patients without prior acute GVHD (Figure 1c ). Of note, the reconstitution pattern of total, naive and memory CD4 + T cells was also influenced by a prior episode of acute GVHD, as shown in Figure 1d . In the entire cohort, and also specifically in the subpopulation of patients not having received ATG during conditioning, absolute numbers of total Tregs, nTregs and mTregs, as well as the frequencies of Treg relative to activated, effector memory and central memory CD4+ T cells at 3, 6 and 12 months post HSCT were not associated with the occurrence of a later episode of chronic GVHD up to 2 years post HSCT. Abbreviations: ATG: anti-thymoglobulin; CB = cord blood; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning.
Treg reconstitution after allogeneic HSCT A Xhaard et al DISCUSSION Few studies have described factors influencing Treg reconstitution. In this large longitudinal cohort of patients, we described Treg reconstitution after allogeneic HSCT and observed correlations with acute and chronic GVHD. We showed that total Treg, nTreg and mTreg reconstitution was delayed after HSCT and remained below the normal range for up to 2 years after HSCT. Total Treg reconstitution after HSCT was mostly due to an increase in mTregs. Reduced-intensity conditioning regimen and PBSC as the source of stem cells were associated with a better short-term reconstitution. In multivariate analysis, PBSC, recipient age ⩽ 25 years and absence of ATG in the conditioning regimen were associated with a better Treg reconstitution. Naive Treg long-term reconstitution was mainly influenced by recipient age. Patients transplanted for acute leukemia had a better long-term Treg reconstitution than patients transplanted for other malignant hematological diseases. Prior acute GVHD impaired Treg and CD4 reconstitution. Treg subsets (absolute numbers and frequencies relative to CD4 + T-cell subsets) at 3, 6 and 12 months after HSCT were not associated with the occurrence of a later episode of chronic GVHD.
The influence of the source of stem cells on Treg reconstitution has been previously reported. In a cohort of 40 pediatric patients, 12 1-year Treg reconstitution did not differ according to the source of stem cells (cord blood or BM). However, two large studies in adults, 13, 14 reported a better 6-month Treg reconstitution after PBSC than after cord blood transplantation. In the study by Jacobson et al.
14 normal Treg numbers were not obtained until 18-24 months after transplantation, whereas in our population, Treg remained below the levels of healthy controls until 24 months after HSCT. The predominant increase of mTregs after HSCT fits with the findings of Matsuoka et al., 7 who reported a predominance of the activated/memory Treg phenotype after HSCT. Matthews et al. 5 in a small series of 25 patients suggested that, beyond 3 months, the Treg numbers and their frequencies among CD4 + T cells gradually increased in patients developing chronic GVHD compared with patients without chronic GVHD. However, in our far larger series we did not find any correlation between GVHD and numbers of total Tregs, nTregs or mTregs, or their ratio to CD4 + T cells or their subsets. Our study has limitations. As samples were obtained at predefined time points, we were not able to determine CD4 + and Treg numbers at acute or chronic GVHD diagnosis. However, + T cells according to the absence or presence of prior aGVHD. Median and 25th/75th percentiles are shown. *P ⩽ 0.04, **P = 0.007, ***P = 0.001. our study is one of the first to describe factors influencing Treg reconstitution. Our population is not homogeneous, which could lead to possible confounding factors in the study of Treg reconstitution. However, this is ruled out by the multivariate analysis, which adjusts for these factors. We believe these data are of particular interest regarding ongoing Treg interventional studies in humans in the context of HSCT.
